Advancements in Psychiatry: Exploring New Horizons in Mental Health
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy in Clinical Medicine".
Deadline for manuscript submissions: 25 May 2026 | Viewed by 908
Special Issue Editors
Interests: psychiatry; psychopharmacology; psychooncology; cognitive behavioral therapy; eating disorders
Special Issue Information
Dear Colleagues,
According to the World Health Organization, one in every eight people is living with a mental disorder, making these illnesses among the most frequently met health problems worldwide. New approaches in the diagnosis and treatment of mental disorders are acutely needed due to the high prevalence and important rates of treatment resistance of severe psychiatric disorders (SPDs) and their significant social and economic impact. Also, the post-modernistic society creates a vulnerable terrain for the development of new diagnostic entities that could significantly impact the quality of life and overall functionality of affected individuals; therefore, mental health specialists have to be aware of these new diagnostic challenges.
This topic aims to expand the current scientific knowledge on five important dimensions related to the new frontiers in psychiatry:
(1) Diagnostic entities such as ultra-processed food addiction, social network site addiction, or problematic use of the internet have been explored in the last two decades, and an increase in awareness about the existence of such disorders in vulnerable populations (e.g., children and adolescents and patients with other psychiatric diagnoses) is needed.
(2) Changes in the nosographic classifications (DSM-5 TR and ICD-11) are important to explore comparatively because this approach is expected to have an impact on clinical and epidemiological research in psychiatry, e.g., dimensional vs. categorical models of personality disorders (ICD-11 vs. ICD-10), or adding gambling disorder in the chapter dedicated to “substance-related and addictive disorders” (DSM-5 vs. DSM-IV TR).
(3) New psychotropic drugs are in the pipeline, and they represent important hopes for patients with SPDs, e.g., new antipsychotics with non-dopaminergic mechanisms, new antidepressants with glutamatergic modulating properties, new anxiolytics derived from androstadienol, immune therapy for Alzheimer’s neurocognitive disorder, etc.
(4) A lack of validated biomarkers for the diagnosis and monitoring of mental disorders is a major obstacle to formulating adequate prophylactic and diagnostic strategies for SPDs; therefore, clinical and translational research targeting such biomarkers is strongly needed.
(5) Non-pharmacological therapies for SPDs are also evolving, e.g., neuromodulation techniques, nutritional interventions, and new psychotherapies, and they can increase the chances of recovery in this population.
We are inviting authors to submit their original work, which may represent clinical studies, translational research, epidemiological studies, literature reviews, and meta-analyses that approach the above-mentioned domains of interest, with the hope that exploring new frontiers of mental health will increase the chances for recovery in patients with psychiatric disorders.
Dr. Octavian Vasiliu
Prof. Dr. Rajendra D. Badgaiyan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- psychopharmacology
- antipsychotics
- antidepressants
- major depressive disorder
- schizophrenia spectrum disorders
- anxiety disorders
- gut microbiota
- neuromodulation
- nutritional psychiatry
- nosographic classifications
- biomarkers
- new diagnoses
- food addiction
- behavioral addictions
- gaming disorder
- internet use disorder
- gambling disorder
- gut microbiota
- avatar therapy
- mindfulness therapy
- transcranial magnetic stimulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
